Fresenius Medical Care AG & Co. KGaA

NYSE:FMS

Medical - Care Facilities

Healthcare
$20.95 -0.76%

-$0.18 today

Market cap
$11.26B
Beta
0.81
P/E (TTM)
11.9
EPS (TTM)
$3.43
Dividend yield
3.65%
52W Low $20.02High $28.87

Volume 1.92M

Average 0.72M

FMS Cost of Revenue

Direct costs of producing the goods and services sold, such as materials, manufacturing, and service delivery.

Fresenius Medical Care AG & Co. KGaANYSE: FMS

Cost of Revenue · Q2 FY2026 · quarter ended Jun 2026

Cost of revenue declines year over year

Q2 FY2026 cost of revenue of €3.55B fell 0.7% year over year, ahead of the -2.7% change in trailing-twelve-month cost of revenue. Sequentially, it rose 3.4% from the prior quarter. Over 3 fiscal years it compounded at +0.2% a year.

Context

  • Cost of revenue amounted to 74.4% of revenue in FY2025, down 1.0 pp from a year earlier.
  • Cost of revenue increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of -0.7% holds above the trailing-twelve-month pace of -2.7%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
€3.55B+3.4% QoQ
Last fiscal yearDec 2025
€14.6B+0.1% YoY
LTMJun 2026
€14.31B-2.7% YoY
Cost of Revenue past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-0.7%——
1 year+0.1%——
3-year CAGR+0.2%——
5-year CAGR——
10-year CAGR——

Cost of Revenue history

EUR · from the income statement

Latest · FY2025
14.6B EUR
Year-over-year change
+0.1%
4-year CAGR
+3.2%

Cost of Revenue vs competitors

How FMS compares with its peers on the latest reported figures

  • Peers report in different currencies, so cost of revenue is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -2.7% is the 3rd highest of 4, against a peer median of +8.8%.
  • Cost of revenue amounts to 73.6% of revenue for FMS, versus a peer median of 19.1%.
FMS Competitors
Cost of Revenue for FMS and competitors
Company Period LTM YoY 3-year CAGR% of revenue
FMSFresenius Medical Care AG & Co. KGaALTM Jun 2026€14.31B EUR-2.7%+0.2%73.6%
DVADaVita Inc.LTM Jun 2026$9.66B USD+8.8%+6.7%69.0%
AKBAAkebia Therapeutics, Inc.LTM Mar 2026$44.46M USD-11.9%+20.6%19.1%
TVTXTravere Therapeutics, Inc.LTM Sep 2026$31.49M USD+204.6%+32.7%4.8%
Peer median (excluding FMS) —+8.8%+20.6%19.1%

Competitors are the stored peer set for FMS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

EUR
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue17.62B19.4B19.45B19.34B19.63B
Cost of Revenue12.85B14.5B14.53B14.58B14.6B
Gross Profit4.77B4.89B4.93B4.76B5.03B
Gross Margin27.1%25.2%25.3%24.6%25.6%
Research & Development220.78M228.62M231.97M183.49M157.98M
Selling, General & Admin2.77B3.17B3.2B3.14B3.03B
Operating Expenses2.92B3.38B3.56B3.29B3.2B
Depreciation & Amortization1.62B1.84B1.75B1.74B1.5B
EBITDA3.55B3.42B3.21B3.21B3.4B
EBITDA Margin20.1%17.6%16.5%16.6%17.3%
Operating Income1.85B1.51B1.37B1.47B1.83B
Operating Margin10.5%7.8%7.0%7.6%9.3%
Interest Income73.17M67.66M88.22M71.58M69.61M
Interest Expense353.6M360.14M424.64M407.04M384.41M
Other Income / Expenses(280.43M)(292.48M)(336.42M)(410.45M)(314.59M)
Income Before Tax1.57B1.22B1.03B1.06B1.51B
Pre-Tax Margin8.9%6.3%5.3%5.5%7.7%
Income Tax Expense352.83M324.95M300.56M316.06M320.97M
Net Income969.31M673.41M499M537.91M978.37M
Net Margin5.5%3.5%2.6%2.8%5.0%
EPS (Basic)0.830.570.850.921.68
EPS (Diluted)0.830.570.850.921.68
Weighted Avg Shares1.17B1.17B586.83M586.83M582.38M
Weighted Avg Shares (Diluted)1.17B1.17B586.83M586.83M582.38M

Fresenius Medical Care AG & Co. KGaA

NYSE:FMS

Intrinsic Alpha fair value

Locked

Current Price

$20.95

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.